Successful treatment of idiopathic pulmonary capillaritis with intravenous cyclophosphamide.
Identifieur interne : 000361 ( PubMed/Curation ); précédent : 000360; suivant : 000362Successful treatment of idiopathic pulmonary capillaritis with intravenous cyclophosphamide.
Auteurs : Frances Flanagan [Irlande (pays)] ; Louisa Glackin ; Dubhfeasa M. SlatterySource :
- Pediatric pulmonology [ 1099-0496 ] ; 2013.
Descripteurs français
- KwdFr :
- Cyclophosphamide (administration et posologie), Cyclophosphamide (usage thérapeutique), Enfant, Humains, Hémosidérose (diagnostic), Hémosidérose (traitement médicamenteux), Immunosuppresseurs (administration et posologie), Immunosuppresseurs (usage thérapeutique), Maladies pulmonaires (diagnostic), Maladies pulmonaires (traitement médicamenteux), Mâle, Perfusions veineuses.
- MESH :
- administration et posologie : Cyclophosphamide, Immunosuppresseurs.
- diagnostic : Hémosidérose, Maladies pulmonaires.
- traitement médicamenteux : Hémosidérose, Maladies pulmonaires.
- usage thérapeutique : Cyclophosphamide, Immunosuppresseurs.
- Enfant, Humains, Mâle, Perfusions veineuses.
English descriptors
- KwdEn :
- Child, Cyclophosphamide (administration & dosage), Cyclophosphamide (therapeutic use), Hemosiderosis (diagnosis), Hemosiderosis (drug therapy), Humans, Immunosuppressive Agents (administration & dosage), Immunosuppressive Agents (therapeutic use), Infusions, Intravenous, Lung Diseases (diagnosis), Lung Diseases (drug therapy), Male.
- MESH :
- chemical , administration & dosage : Cyclophosphamide, Immunosuppressive Agents.
- chemical , therapeutic use : Cyclophosphamide, Immunosuppressive Agents.
- diagnosis : Hemosiderosis, Lung Diseases.
- drug therapy : Hemosiderosis, Lung Diseases.
- Child, Humans, Infusions, Intravenous, Male.
Abstract
Idiopathic pulmonary hemosiderosis (IPH), a subtype of diffuse alveolar hemorrhage is a rare condition, first described by Virchow in 1864. Historically, it manifests in children in the first decade of life with the combination of hemoptysis, iron deficiency anemia, and alveolar infiltrates on chest radiograph. More recently, diffuse alveolar hemorrhage has been classified by the absence or presence of pulmonary capillaritis (PC), the latter carrying a potential for a poorer outcome. While systemic corticosteroids remain the first line treatment option, other immune modulators have been trailed including hydroxychloroquine, azathioprine, 6-mercaptopurine, and cyclophosphamide with varying results. Our case demonstrates for the first time, the successful use of intravenous cyclophosphamide in the management of chronic idiopathic PC.
DOI: 10.1002/ppul.22583
PubMed: 22573417
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000361
Links to Exploration step
pubmed:22573417Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Successful treatment of idiopathic pulmonary capillaritis with intravenous cyclophosphamide.</title><author><name sortKey="Flanagan, Frances" sort="Flanagan, Frances" uniqKey="Flanagan F" first="Frances" last="Flanagan">Frances Flanagan</name><affiliation wicri:level="1"><nlm:affiliation>Department of Respiratory Medicine, Children's University Hospital, Dublin, Ireland. fraflanagan@gmail.com</nlm:affiliation><country xml:lang="fr">Irlande (pays)</country><wicri:regionArea>Department of Respiratory Medicine, Children's University Hospital, Dublin</wicri:regionArea></affiliation></author><author><name sortKey="Glackin, Louisa" sort="Glackin, Louisa" uniqKey="Glackin L" first="Louisa" last="Glackin">Louisa Glackin</name></author><author><name sortKey="Slattery, Dubhfeasa M" sort="Slattery, Dubhfeasa M" uniqKey="Slattery D" first="Dubhfeasa M" last="Slattery">Dubhfeasa M. Slattery</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:22573417</idno><idno type="pmid">22573417</idno><idno type="doi">10.1002/ppul.22583</idno><idno type="wicri:Area/PubMed/Corpus">000361</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000361</idno><idno type="wicri:Area/PubMed/Curation">000361</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000361</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Successful treatment of idiopathic pulmonary capillaritis with intravenous cyclophosphamide.</title><author><name sortKey="Flanagan, Frances" sort="Flanagan, Frances" uniqKey="Flanagan F" first="Frances" last="Flanagan">Frances Flanagan</name><affiliation wicri:level="1"><nlm:affiliation>Department of Respiratory Medicine, Children's University Hospital, Dublin, Ireland. fraflanagan@gmail.com</nlm:affiliation><country xml:lang="fr">Irlande (pays)</country><wicri:regionArea>Department of Respiratory Medicine, Children's University Hospital, Dublin</wicri:regionArea></affiliation></author><author><name sortKey="Glackin, Louisa" sort="Glackin, Louisa" uniqKey="Glackin L" first="Louisa" last="Glackin">Louisa Glackin</name></author><author><name sortKey="Slattery, Dubhfeasa M" sort="Slattery, Dubhfeasa M" uniqKey="Slattery D" first="Dubhfeasa M" last="Slattery">Dubhfeasa M. Slattery</name></author></analytic><series><title level="j">Pediatric pulmonology</title><idno type="eISSN">1099-0496</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Child</term><term>Cyclophosphamide (administration & dosage)</term><term>Cyclophosphamide (therapeutic use)</term><term>Hemosiderosis (diagnosis)</term><term>Hemosiderosis (drug therapy)</term><term>Humans</term><term>Immunosuppressive Agents (administration & dosage)</term><term>Immunosuppressive Agents (therapeutic use)</term><term>Infusions, Intravenous</term><term>Lung Diseases (diagnosis)</term><term>Lung Diseases (drug therapy)</term><term>Male</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Cyclophosphamide (administration et posologie)</term><term>Cyclophosphamide (usage thérapeutique)</term><term>Enfant</term><term>Humains</term><term>Hémosidérose (diagnostic)</term><term>Hémosidérose (traitement médicamenteux)</term><term>Immunosuppresseurs (administration et posologie)</term><term>Immunosuppresseurs (usage thérapeutique)</term><term>Maladies pulmonaires (diagnostic)</term><term>Maladies pulmonaires (traitement médicamenteux)</term><term>Mâle</term><term>Perfusions veineuses</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Cyclophosphamide</term><term>Immunosuppressive Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Cyclophosphamide</term><term>Immunosuppressive Agents</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Cyclophosphamide</term><term>Immunosuppresseurs</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Hemosiderosis</term><term>Lung Diseases</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Hémosidérose</term><term>Maladies pulmonaires</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Hemosiderosis</term><term>Lung Diseases</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Hémosidérose</term><term>Maladies pulmonaires</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Cyclophosphamide</term><term>Immunosuppresseurs</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Child</term><term>Humans</term><term>Infusions, Intravenous</term><term>Male</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Enfant</term><term>Humains</term><term>Mâle</term><term>Perfusions veineuses</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Idiopathic pulmonary hemosiderosis (IPH), a subtype of diffuse alveolar hemorrhage is a rare condition, first described by Virchow in 1864. Historically, it manifests in children in the first decade of life with the combination of hemoptysis, iron deficiency anemia, and alveolar infiltrates on chest radiograph. More recently, diffuse alveolar hemorrhage has been classified by the absence or presence of pulmonary capillaritis (PC), the latter carrying a potential for a poorer outcome. While systemic corticosteroids remain the first line treatment option, other immune modulators have been trailed including hydroxychloroquine, azathioprine, 6-mercaptopurine, and cyclophosphamide with varying results. Our case demonstrates for the first time, the successful use of intravenous cyclophosphamide in the management of chronic idiopathic PC.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22573417</PMID><DateCompleted><Year>2013</Year><Month>08</Month><Day>09</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1099-0496</ISSN><JournalIssue CitedMedium="Internet"><Volume>48</Volume><Issue>3</Issue><PubDate><Year>2013</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Pediatric pulmonology</Title><ISOAbbreviation>Pediatr. Pulmonol.</ISOAbbreviation></Journal><ArticleTitle>Successful treatment of idiopathic pulmonary capillaritis with intravenous cyclophosphamide.</ArticleTitle><Pagination><MedlinePgn>303-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/ppul.22583</ELocationID><Abstract><AbstractText>Idiopathic pulmonary hemosiderosis (IPH), a subtype of diffuse alveolar hemorrhage is a rare condition, first described by Virchow in 1864. Historically, it manifests in children in the first decade of life with the combination of hemoptysis, iron deficiency anemia, and alveolar infiltrates on chest radiograph. More recently, diffuse alveolar hemorrhage has been classified by the absence or presence of pulmonary capillaritis (PC), the latter carrying a potential for a poorer outcome. While systemic corticosteroids remain the first line treatment option, other immune modulators have been trailed including hydroxychloroquine, azathioprine, 6-mercaptopurine, and cyclophosphamide with varying results. Our case demonstrates for the first time, the successful use of intravenous cyclophosphamide in the management of chronic idiopathic PC.</AbstractText><CopyrightInformation>Copyright © 2012 Wiley Periodicals, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Flanagan</LastName><ForeName>Frances</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Children's University Hospital, Dublin, Ireland. fraflanagan@gmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glackin</LastName><ForeName>Louisa</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Slattery</LastName><ForeName>Dubhfeasa M</ForeName><Initials>DM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>05</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Pediatr Pulmonol</MedlineTA><NlmUniqueID>8510590</NlmUniqueID><ISSNLinking>1099-0496</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>8N3DW7272P</RegistryNumber><NameOfSubstance UI="D003520">Cyclophosphamide</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C536281">Idiopathic pulmonary hemosiderosis</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003520" MajorTopicYN="N">Cyclophosphamide</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006486" MajorTopicYN="N">Hemosiderosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007262" MajorTopicYN="N">Infusions, Intravenous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008171" MajorTopicYN="N">Lung Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>10</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>04</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>5</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>5</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>8</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22573417</ArticleId><ArticleId IdType="doi">10.1002/ppul.22583</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000361 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000361 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:22573417
|texte= Successful treatment of idiopathic pulmonary capillaritis with intravenous cyclophosphamide.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:22573417" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a ChloroquineV1
| This area was generated with Dilib version V0.6.33. |  |